28
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      The circRNA–microRNA code: emerging implications for cancer diagnosis and treatment

      review-article

      Read this article at

      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Circular RNAs (circ RNAs) comprise an emerging new class of endogenous RNAs expressed abundantly by the eukaryotic transcriptome. They are characterized by a covalently closed loop structure, resulting in RNA molecules that are more stable than linear RNAs. A growing number of studies indicate that circ RNAs play critical roles in human diseases and show great potential as biomarkers and therapeutic targets. The molecular events determined by circ RNA activity, the circ RNA code, involve other types of noncoding RNA molecules, primarily micro RNAs, long noncoding RNAs, and RNA‐binding proteins. Herein, we mainly focus on the circ RNA–micro RNA code, showing how this relationship impacts the regulation of gene expression in cancer. The emerging roles for circ RNAs in oncogenic pathways highlight new perspectives for the detailed molecular dissection of cancer pathogenesis and, at the same time, offer new opportunities to design innovative therapeutic strategies. Here, we review recent research advancements in understanding the biogenesis, molecular functions, and significance of circ RNAs in cancer diagnosis and treatment.

          Related collections

          Most cited references16

          • Record: found
          • Abstract: found
          • Article: not found

          Dishevelled: The hub of Wnt signaling.

          Wnt signaling controls a variety of developmental and homeostatic events. As a key component of Wnt signaling, Dishevelled (Dvl/Dsh) protein relays Wnt signals from receptors to downstream effectors. In the canonical Wnt pathway that depends on the nuclear translocation of beta-catenin, Dvl is recruited by the receptor Frizzled and prevents the constitutive destruction of cytosolic beta-catenin. In the non-canonical Wnt pathways such as Wnt-Frizzled/PCP (planar cell polarity) signaling, Dvl signals via the Daam1-RhoA axis and the Rac1 axis. In addition, Dvl plays important roles in Wnt-GSK3beta-microtubule signaling, Wnt-calcium signaling, Wnt-RYK signaling, Wnt-atypical PKC signaling, etc. Dvl also functions to mediate receptor endocytosis. To fulfill its multifaceted functions, it is not surprising that Dvl associates with various kinds of proteins. Its activity is also modulated dynamically by phosphorylation, ubiquitination and degradation. In this review, we summarize the current understanding of Dvl functions in Wnt signal transduction and its biological functions in mouse development, and also discuss the molecular mechanisms of its actions. 2009 Elsevier Inc. All rights reserved.
            Bookmark
            • Record: found
            • Abstract: found
            • Article: not found

            MicroRNA-7 inhibits tumor growth and metastasis by targeting the phosphoinositide 3-kinase/Akt pathway in hepatocellular carcinoma.

            MicroRNAs (miRNAs) are known to be involved in carcinogenesis and tumor progression in hepatocellular carcinoma (HCC). Recently, microRNA-7 (miR-7) has been proven to play a substantial role in glioblastoma and breast cancer, but its functions in the context of HCC remain unknown. Here, we demonstrate that miR-7 inhibits HCC cell growth and metastasis in vitro and in vivo. We first screened and identified a novel miR-7 target, phosphoinositide 3-kinase catalytic subunit delta (PIK3CD). Overexpression of miR-7 would specifically and markedly down-regulate its expression. miR-7-overexpressing subclones showed significant cell growth inhibition by G(0) /G(1) -phase cell-cycle arrest and significant impairment of cell migration in vitro. To identify the mechanisms, we investigated the phosphoinositide 3-kinase (PI3K)/Akt pathway and found that Akt, mammalian target of rapamycin (mTOR), and p70S6K were down-regulated, whereas 4EBP1 was up-regulated in miR-7-overexpressing subclones. We also identified two novel, putative miR-7 target genes, mTOR and p70S6K, which further suggests that miR-7 may be a key regulator of the PI3K/Akt pathway. In xenograft animal experiments, we found that overexpressed miR-7 effectively repressed tumor growth (3.5-fold decrease in mean tumor volume; n = 5) and abolished extrahepatic migration from liver to lung in a nude mouse model of metastasis (n = 5). The number of visible nodules on the lung surface was reduced by 32-fold. A correlation between miR-7 and PIK3CD expression was also confirmed in clinical samples of HCC. These findings indicate that miR-7 functions as a tumor suppressor and plays a substantial role in inhibiting the tumorigenesis and reversing the metastasis of HCC through the PI3K/Akt/mTOR-signaling pathway in vitro and in vivo. By targeting PIK3CD, mTOR, and p70S6K, miR-7 efficiently regulates the PI3K/Akt pathway. Given these results, miR-7 may be a potential therapeutic or diagnostic/prognostic target for treating HCC. Copyright © 2012 American Association for the Study of Liver Diseases.
              Bookmark
              • Record: found
              • Abstract: found
              • Article: not found

              Analysis of MiR-195 and MiR-497 expression, regulation and role in breast cancer.

              To investigate expression, regulation, potential role and targets of miR-195 and miR-497 in breast cancer. The expression patterns of miR-195 and miR-497 were initially examined in breast cancer tissues and cell lines by Northern blotting and quantitative real-time PCR. Combined bisulfite restriction analysis and bisulfite sequencing were carried out to study the DNA methylation status of miR-195 and miR-497 genes. Breast cancer cells stably expressing miR-195 and miR-497 were established to study their role and targets. Finally, normal, fibroadenoma and breast cancer tissues were employed to analyze the correlation between miR-195/497 levels and malignant stages of breast tumor tissues. MiR-195 and miR-497 were significantly downregulated in breast cancer. The methylation state of CpG islands upstream of the miR-195/497 gene was found to be responsible for the downregulation of both miRNAs. Forced expression of miR-195 or miR-497 suppressed breast cancer cell proliferation and invasion. Raf-1 and Ccnd1 were identified as novel direct targets of miR-195 and miR-497. miR-195/497 expression levels in clinical specimens were found to be correlated inversely with malignancy of breast cancer. Our data imply that both miR-195 and miR-497 play important inhibitory roles in breast cancer malignancy and may be the potential therapeutic and diagnostic targets.
                Bookmark

                Author and article information

                Contributors
                yosef.yarden@weizmann.ac.il
                giovanni.blandino@ifo.gov.it
                Journal
                Mol Oncol
                Mol Oncol
                10.1002/(ISSN)1878-0261
                MOL2
                Molecular Oncology
                John Wiley and Sons Inc. (Hoboken )
                1574-7891
                1878-0261
                18 February 2019
                April 2019
                : 13
                : 4 ( doiID: 10.1002/mol2.2019.13.issue-4 )
                : 669-680
                Affiliations
                [ 1 ] Unit of Oncogenomic and Epigenetic IRCCS Regina Elena National Cancer Institute Rome Italy
                [ 2 ] Department of Biological Regulation Weizmann Institute of Science Rehovot Israel
                Author notes
                [*] [* ] Correspondence

                Y. Yarden, Department of Biological Regulation, Weizmann Institute of Science, Rehovot, Israel

                Tel: +972‐8‐934 3974

                E‐mail: yosef.yarden@ 123456weizmann.ac.il

                and

                G. Blandino, Unit of Oncogenomic and Epigenetic, IRCCS Regina Elena National Cancer Institute, Rome, Italy

                Tel: +39‐0652662911

                E‐mail: giovanni.blandino@ 123456ifo.gov.it

                Article
                MOL212468
                10.1002/1878-0261.12468
                6441890
                30719845
                35d44f46-1867-4922-b91a-7260d10895bc
                © 2019 The Authors. Published by FEBS Press and John Wiley & Sons Ltd.

                This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.

                History
                : 10 December 2018
                : 16 January 2019
                : 21 January 2019
                Page count
                Figures: 3, Tables: 1, Pages: 12, Words: 7800
                Funding
                Funded by: European Research Council (ERC)
                Funded by: Dr. Miriam and Sheldon G. Adelson Medical Research Foundation
                Funded by: STARTP53 from LazioInnova
                Funded by: Italy‐USA Bilateral Grants
                Funded by: Israel Science Foundation (ISF)
                Funded by: AIRC
                Award ID: 20613
                Funded by: EPIGEN Flagship Project
                Award ID: 13/05/R/42
                Categories
                Review Article
                Review Articles
                Custom metadata
                2.0
                mol212468
                April 2019
                Converter:WILEY_ML3GV2_TO_NLMPMC version:5.6.2.1 mode:remove_FC converted:01.04.2019

                Oncology & Radiotherapy
                cancer,circrna code,circular rnas,micrornas,patients
                Oncology & Radiotherapy
                cancer, circrna code, circular rnas, micrornas, patients

                Comments

                Comment on this article